O	0	8	Outcomes
O	9	11	of
B-ethinicity	12	20	Japanese
O	21	27	breast
O	28	34	cancer
O	35	43	patients
O	44	51	treated
O	52	56	with
O	57	60	pre
O	60	61	-
O	61	70	operative
O	71	74	and
O	75	79	post
O	79	80	-
O	80	89	operative
B-intervention	90	101	anastrozole
O	102	104	or
B-control	105	114	tamoxifen
O	114	115	.

O	116	119	The
O	120	127	present
O	128	133	study
O	134	142	examined
O	143	147	long
O	147	148	-
O	148	152	term
O	153	161	efficacy
O	162	170	outcomes
O	171	173	in
O	174	175	a
O	176	184	subgroup
O	185	187	of
O	188	202	postmenopausal
O	202	203	,
O	204	212	estrogen
O	213	221	receptor
O	221	222	-
O	222	230	positive
O	231	239	Japanese
O	240	246	breast
O	247	253	cancer
O	254	262	patients
O	263	267	from
O	268	271	the
O	272	275	Pre
O	275	276	-
O	276	285	Operative
O	286	287	"
O	287	295	Arimidex
O	295	296	"
O	297	305	Compared
O	306	310	with
O	311	320	Tamoxifen
O	321	326	trial
O	326	327	,
O	328	337	following
O	338	341	pre
O	341	342	-
O	342	351	operative
O	352	353	(
O	353	354	3
O	355	361	months
O	361	362	)
O	363	366	and
O	367	371	post
O	371	372	-
O	372	381	operative
O	382	383	(
O	383	384	5
O	385	390	years
O	390	391	)
O	392	400	adjuvant
O	401	410	treatment
O	411	415	with
O	416	422	either
O	423	434	anastrozole
O	435	437	or
O	438	447	tamoxifen
O	447	448	.

B-eligibility	449	457	Patients
I-eligibility	458	462	with
I-eligibility	463	468	large
I-eligibility	468	469	,
I-eligibility	470	481	potentially
I-eligibility	482	490	operable
I-eligibility	490	491	,
I-eligibility	492	499	locally
I-eligibility	499	500	-
I-eligibility	500	508	advanced
I-eligibility	509	515	breast
I-eligibility	516	522	cancer
O	523	527	were
O	528	538	randomized
O	539	541	to
O	542	549	receive
O	550	561	anastrozole
O	562	563	(
O	563	564	1
O	565	567	mg
O	567	568	/
O	568	571	day
O	571	572	)
O	573	577	plus
O	578	587	tamoxifen
O	588	595	placebo
O	596	598	or
O	599	608	tamoxifen
O	609	610	(
O	610	612	20
O	613	615	mg
O	615	616	/
O	616	619	day
O	619	620	)
O	621	625	plus
O	626	637	anastrozole
O	638	645	placebo
O	646	649	pre
O	649	650	-
O	650	661	operatively
O	661	662	.

O	663	668	After
O	669	676	surgery
O	677	679	at
O	680	681	3
O	682	688	months
O	688	689	,
O	690	698	patients
O	699	708	continued
O	709	711	on
O	712	715	the
O	716	720	same
O	721	726	study
O	727	737	medication
O	738	740	as
O	741	749	adjuvant
O	750	757	therapy
O	758	761	for
O	762	764	up
O	765	767	to
O	768	769	5
O	770	775	years
O	776	778	or
O	779	784	until
O	785	795	recurrence
O	795	796	,
O	797	808	intolerable
O	809	817	toxicity
O	818	820	or
O	821	831	withdrawal
O	832	834	of
O	835	842	patient
O	843	850	consent
O	850	851	.

O	852	862	Recurrence
O	862	863	-
O	863	867	free
O	868	876	survival
O	877	880	and
O	881	888	overall
O	889	897	survival
O	898	902	were
O	903	911	measured
O	912	916	from
O	917	920	the
O	921	925	date
O	926	928	of
O	929	942	randomization
O	943	945	to
O	946	949	the
O	950	954	date
O	955	957	of
O	958	968	recurrence
O	969	971	or
O	972	977	death
O	977	978	,
O	979	988	whichever
O	989	997	occurred
O	998	1003	first
O	1003	1004	.

O	1005	1013	Patients
O	1014	1018	were
O	1019	1028	monitored
O	1029	1032	for
O	1033	1040	adverse
O	1041	1047	events
O	1048	1058	throughout
O	1059	1062	the
O	1063	1068	study
O	1069	1075	period
O	1076	1079	and
O	1080	1082	up
O	1083	1085	to
O	1086	1088	30
O	1089	1093	days
O	1094	1103	following
O	1104	1118	administration
O	1119	1121	of
O	1122	1125	the
O	1126	1130	last
O	1131	1136	study
O	1137	1147	medication
O	1147	1148	.

O	1149	1155	During
O	1156	1160	post
O	1160	1161	-
O	1161	1170	operative
O	1171	1179	adjuvant
O	1180	1187	therapy
O	1187	1188	,
B-iv-bin-abs	1189	1190	4
O	1190	1191	/
B-intervention-participants	1191	1193	48
O	1194	1195	(
B-iv-bin-percent	1195	1196	8
I-iv-bin-percent	1196	1197	%
O	1197	1198	)
O	1199	1210	anastrozole
O	1211	1214	and
B-cv-bin-abs	1215	1217	25
O	1217	1218	/
B-control-participants	1218	1220	49
O	1221	1222	(
B-cv-bin-percent	1222	1224	51
I-cv-bin-percent	1224	1225	%
O	1225	1226	)
O	1227	1236	tamoxifen
O	1237	1245	patients
O	1246	1257	experienced
B-outcome	1258	1268	recurrence
O	1268	1269	.

O	1270	1275	There
O	1276	1279	was
O	1280	1281	a
O	1282	1293	significant
O	1294	1304	difference
O	1305	1307	in
B-outcome	1308	1318	recurrence
I-outcome	1318	1319	-
I-outcome	1319	1323	free
I-outcome	1324	1332	survival
O	1333	1340	between
O	1341	1344	the
O	1345	1348	two
O	1349	1355	groups
O	1356	1357	(
O	1357	1363	hazard
O	1364	1369	ratio
O	1370	1371	0
O	1371	1372	.
O	1372	1374	14
O	1374	1375	;
O	1376	1378	95
O	1378	1379	%
O	1380	1390	confidence
O	1391	1399	interval
O	1400	1401	0
O	1401	1402	.
O	1402	1404	05
O	1404	1405	-
O	1405	1406	0
O	1406	1407	.
O	1407	1409	41
O	1409	1410	;
O	1411	1412	P
O	1413	1414	=
O	1415	1416	0
O	1416	1417	.
O	1417	1421	0003
O	1421	1422	)
O	1422	1423	.

O	1424	1429	There
O	1430	1433	was
O	1434	1435	a
O	1436	1447	significant
O	1448	1456	increase
O	1457	1459	in
B-outcome	1460	1467	overall
I-outcome	1468	1476	survival
O	1477	1481	with
O	1482	1493	anastrozole
O	1494	1495	(
O	1495	1496	0
O	1496	1497	.
O	1497	1499	21
O	1499	1500	;
O	1501	1502	0
O	1502	1503	.
O	1503	1505	05
O	1505	1506	-
O	1506	1507	0
O	1507	1508	.
O	1508	1510	96
O	1510	1511	;
O	1512	1513	P
O	1514	1515	=
O	1516	1517	0
O	1517	1518	.
O	1518	1522	0436
O	1522	1523	)
O	1524	1527	and
O	1528	1533	there
O	1534	1538	were
B-iv-bin-abs	1539	1540	2
O	1540	1541	/
B-intervention-participants	1541	1543	48
O	1544	1545	(
B-iv-bin-percent	1545	1546	4
I-iv-bin-percent	1546	1547	%
O	1547	1548	)
O	1549	1552	and
B-cv-bin-abs	1553	1555	10
O	1555	1556	/
B-control-participants	1556	1558	49
O	1559	1560	(
B-cv-bin-percent	1560	1562	20
I-cv-bin-percent	1562	1563	%
O	1563	1564	)
B-outcome	1565	1571	deaths
O	1572	1576	with
O	1577	1588	anastrozole
O	1589	1592	and
O	1593	1602	tamoxifen
O	1602	1603	,
O	1604	1616	respectively
O	1616	1617	.

O	1618	1622	Most
O	1623	1631	patients
O	1632	1642	responding
O	1643	1645	to
O	1646	1649	pre
O	1649	1650	-
O	1650	1659	operative
O	1660	1667	therapy
O	1668	1676	remained
B-outcome	1677	1687	recurrence
I-outcome	1687	1688	-
I-outcome	1688	1692	free
O	1692	1693	.

O	1694	1704	Sequential
O	1705	1708	pre
O	1708	1709	-
O	1709	1718	operative
O	1718	1719	/
O	1719	1723	post
O	1723	1724	-
O	1724	1733	operative
O	1734	1743	treatment
O	1744	1748	with
O	1749	1760	anastrozole
O	1761	1769	resulted
O	1770	1772	in
O	1773	1778	lower
O	1779	1789	recurrence
O	1790	1793	and
O	1794	1799	death
O	1800	1805	rates
O	1805	1806	,
O	1807	1815	compared
O	1816	1820	with
O	1821	1830	tamoxifen
O	1830	1831	.
